Akorn said that this approval is the company’s first lyophilized product approval for manufacture in its Decatur, Illinois production facility.
Akorn has invested approximately $23 million in a new liquid and lyophilized injectable manufacturing fill line at its Decatur, Illinois production facility.
Arthur Przybyl, Akorn’s president and CEO, said: “We intend to commercialize our lyophilization manufacturing capabilities by developing an internal abbreviated new drug application injectable product line and by expanding our contract pharmaceutical manufacturing business segment to include lyophilized injectable products.”